Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice

Behavioural Brain Research

Volumn 147, Issue 1-2, 2003, Pages 175-184

  Nic Dhonnchadha, Bríd Áine ^a   Hascoët, Martine ^a   Jolliet, Pascale ^a   Bourin, Michel ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

5 HT2A receptor; Anxiolysis; DOI; EPM; FPT

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 2 PROPEN 1 ONE 1 (2 FLUOROPHENYL) 3 (4 HYDROXYPHENYL) O [2 (DIMETHYLAMINO)ETHYL]OXIME; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 8 [5,2,4 DIMETHOXY 5 (4 TRIFLUOROMETHYLPHENYLSULFONAMIDO)PHENYL 5 OXOPENTYL] 1,3,8 TRIAZASPIRO[4,5]DECANE 2,4 DIONE; SEROTONIN 2A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C ANTAGONIST; UNCLASSIFIED DRUG; ANXIOLYTIC AGENT; DIAZEPAM; DIMETHOXY 4 INDOPHENYL 2 AMINOPROPANE; DIMETHOXY-4-INDOPHENYL-2-AMINOPROPANE; DRUG DERIVATIVE; INDOPHENOL; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; EXPERIMENTAL TEST; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PUNISHMENT; RECEPTOR AFFINITY; TRANQUILIZING ACTIVITY; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INTERACTION; DRUG POTENTIATION; ELECTRIC SHOCK; ESCAPE BEHAVIOR; METABOLISM; MOTOR ACTIVITY; TIME;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROSHOCK; ESCAPE REACTION; INDOPHENOL; MALE; MICE; MOTOR ACTIVITY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; TIME FACTORS;

EID: 0345171044     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(03)00179-7     Document Type: Article

References (46)

1. 2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology. 20:1999;92-96.
2. Aron C., Simon P., Larousse C., Boissier J.R. Evaluation of a rapid technique detecting minor tranquilizers. Neuropharmacology. 10:1971;459-469.
3. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 38:1999;1083-1152.
4. 2 receptor subtypes: a family re-united? TIPS. 105:1995;105-110.
5. Boissier J.R., Simon P. Action de la caféine sur la motilité spontanée de la souris. Arch Int. Pharmacodyn. 158:1965;212-221.
6. 2C receptor antagonist, RS 10-2221. Ann. N.Y. Acad. Sci. 861:1998;269.
7. 2C receptor antagonist. Neuropharmacology. 36:1997;621-629.
8. 2A receptors. Eur. J. Pharmacol. 334:1997;25-29.
9. 2-receptor interactions. Pharmacol. Biochem. Behav. 37:1990;95-99.
10. Dawson G.R., Tricklebank M.D. Use of the elevated plus maze in the search for novel anxiolytic agents. TIPS. 16:1995;33-36.
11. Gaggi R., Dall'olio R., Roncada P. Effects of the selective 5-HT receptor agonists 8-OHDPAT and DOI on behaviour and brain biogenic amines of rats. Gen. Pharmacol. 28:1997;583-587.
12. 2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology. 38:1999;315-317.
13. Grobin A.C., Deutch A.Y. Dopaminergic regulation of extracellular GABA levels in the prefrontal cortex. J. Pharm. Exp. Ther. 285:1998;350-357.
14. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more then 30 years of research. Pharmacol. Ther. 65:1995;319-395.
15. Handley S.L., Mcblane J.W. An assessment of the elevated X maze for studying anxiety and anxiety-modulating drugs. J. Pharmacol. Toxicol. Methods. 29:1993;129-138.
16. Hascoët M., Bourin M., Colombel M.C., Fiocco A., Baker G.B. Anxiolytic-like effects of antidepressants in a four-plate test in mice. Pharmacol. Biochem. Behav. 65(2):2000;339-344.
17. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 54:1996;21-30.
18. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71:2002;533-554.
19. 2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Brain Res. 907:2001;151-155.
20. 2 receptor subtypes. Eur. J. Pharmacol. 414:2001;23-30.
21. 2A antagonist with a favourable CNS safety profile. J. Pharmacol. Exp. Ther. 277:1996;968-981.
22. Kelland MD, Chiodo LA. Serotoninergic modulation of midbrain dopamine systems. In: Ashby CR, editor. The modulation of dopaminergic neurotransmission by other neurotransmitters. New York: CRC Press; 1996. p. 87-122.
23. 2C receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology. 114:1994;90-96.
24. 2B receptor antagonist with anxiolytic properties. Br. J. Pharmacol. 117:1996;427-434.
25. Kozuru T., Kagaya A., Takebayashi M., Horiguchi J., Yamawaki S. Chronic electroconvulsive shock decreases (+/-) 1-(4-iodo-2,5-dimethoxyphenyl)-2- aminopropane hydrochloride (DOI)-induced wet-dog shake behaviours of dexmethasone-treated rats. Life Sci. 66:2000;1271-1279.
26. 2 antagonist. Mol. Pharmacol. 27:1985;600-611.
27. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology. 92:1987;180-185.
28. 2A receptors. Psychopharmacology. 117:1995;193-199.
29. Nakamura K., Kurasawa M. Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur. J. Pharmacol. 420:2001;33-43.
30. 2 ligands on three mouse models of anxiety. Behav. Brain Res. 140:2003;203-214.
31. Onaivi E.S., Bishop-Robinson C., Darmani N.A., Sanders-Bush E. Behavioural effects of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, (DOI) in the elevated plus maze test. Life Sci. 57:1995;2455-2466.
32. Pazos A., Cortés R., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in rat brain. II Serotonin-2 receptors. Brain Res. 346:1985;231-249.
33. 2A antagonist attenuates dopamine release in the rat medial prefrontal cortex. Brain Res. 888:2001;51-59.
34. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
35. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus maze: a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. 24:1986;525-529.
36. Pierce P.A., Peroutka S.J. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology. 97:1989;118-122.
37. 2C receptors. Mol. Brain Res. 23:1994;163-178.
38. 2C receptors in CHO-K1 cells. Br. J. Pharmacol. 128:1999;13-20.
39. Ramos A., Berton O., Mormede P., Chaouloff F. A multiple test study of anxiety-related behaviours in six inbred rat strains. Behav. Brain Res. 85:1997;57-69.
40. 2 receptor antagonist. J. Pharmacol. Exp. Ther. 262:1992;759-768.
41. 1A agonists. J. Pharmacol. Exp. Ther. 273:1995;101-112.
42. Schreiber R., Melon C., De Vry J. The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin inhibitors in the rat ultrasonic vocalisation test. Psychopharmacology. 135:1998;383-391.
43. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology. 94:1988;213-216.
44. 2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J. Neurosci. 21:1999;3572-3579.
45. Van Wijngaarden I., Tulp M.T.M., Soudijn W. The concept of selectivity in 5-HT receptor research. Eur. J. Pharmacol. 188:1990;301-312.
46. Vasar E., Lang A., Harro J., Bourin M., Bradwejn J. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus maze. Neuropharmacology. 33:1994;729-735.